Bavisant

Bavisant (JNJ-31001074) is an orally active, potent, brain-penetrating and highly selective antagonist of the histamine H3 receptor. Bavisant can be used for attention-deficit hyperactivity disorder (ADHD) research[1][2][3].

Product Specifications

CAS Number

[929622-08-2]

Product Name Alternative

JNJ-31001074

UNSPSC

12352005

Target

Histamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Neurological Disease; Endocrinology

Assay Protocol

https://www.medchemexpress.com/bavisant.html

Purity

96.60

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N1CCN(C2CC2)CC1)C(C=C3)=CC=C3CN4CCOCC4

Molecular Formula

C19H27N3O2

Molecular Weight

329.44

References & Citations

[1]Hudkins RL, et al. Discovery and characterization of 6-{4-[3- (R) -2-methylpyrrolidin-1-yl) propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant) : a potent, selective histamine H3 receptor inverse agonist. J Med Chem. 2011 Jul 14;54 (13) :4781-92.|[2]Weisler RH, et al. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012 May 1;26 (5) :421-34.|[3]Ghoshal A, et al. Identification of novel β-lactams and pyrrolidinone derivatives as selective Histamine-3 receptor (H3R) modulators as possible anti-obesity agents. Eur J Med Chem. 2018 May 25;152:148-159. |[4]Ghamari N, et al. Histamine H3 receptor antagonists/inverse agonists: Where do they go? Pharmacol Ther. 2019 Aug;200:69-84.